XAB-5 is under clinical development by Xenothera and currently in Phase I for Bacterial Infections. According to GlobalData, Phase I drugs for Bacterial Infections have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how XAB-5’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
XAB-5 is under development for the treatment of multi drug resistant (MDR) bacterial infections. The drug candidate is a polyclonal antibody developed based on Xenothera technology platform involving generation of hyperimmune polyclonal sera. It is administered through intravenous route.
Xenothera, is a xenotherapy platform with embedded technology that renovates immunological treatments. The company is headquartered in France.
For a complete picture of XAB-5’s drug-specific PTSR and LoA scores, buy the report here.